UBE2O Polyklonaler Antikörper

• Featured Product
• KD/KO Validated

UBE2O Polyklonal Antikörper für IHC, WB,ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human

Anwendung

WB, IHC, IF, ELISA

Konjugation

Unkonjugiert

Publikationen

4

Kat-Nr. : 15812-1-AP

Synonyme

E2-230K, KIAA1734, UBE2O, Ubiquitin carrier protein O, Ubiquitin protein ligase O

---

Galerie der Validierungsdaten

• 

  WB analysis of HeLa using 15812-1-AP

  HeLa cells were subjected to SDS PAGE followed by western blot with 15812-1-AP (UBE2O antibody) at dilution of 1:500 incubated at room temperature for 1.5 hours.

• 

  WB analysis of A431 using 15812-1-AP

  A431 cells were subjected to SDS PAGE followed by western blot with 15812-1-AP (UBE2O antibody) at dilution of 1:500 incubated at room temperature for 1.5 hours.

• 

  WB analysis of Jurkat using 15812-1-AP

  Jurkat cells were subjected to SDS PAGE followed by western blot with 15812-1-AP (UBE2O antibody) at dilution of 1:500 incubated at room temperature for 1.5 hours.

• 

  IHC staining of human heart using 15812-1-AP

  Immunohistochemical analysis of paraffin-embedded human heart tissue slide using 15812-1-AP (UBE2O Antibody) at dilution of 1:200 (under 10x lens).

• 

  IHC staining of human heart using 15812-1-AP

  Immunohistochemical analysis of paraffin-embedded human heart tissue slide using 15812-1-AP (UBE2O Antibody) at dilution of 1:200 (under 40x lens).

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in WB: HeLa-Zellen, A431-Zellen, Jurkat-Zellen
• Erfolgreiche Detektion in IHC: humanes Herzgewebe; Hinweis: Antigendemaskierung mit TE-Puffer pH 9,0 empfohlen. (*) Wahlweise kann die Antigendemaskierung auch mit Citratpuffer pH 6,0 erfolgen.

Empfohlene Verdünnung

• Western Blot (WB): WB : 1:500-1:1000
• Immunhistochemie (IHC): IHC : 1:100-1:400

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Veröffentlichte Anwendungen

• KD/KO: See 2 publications below
• WB: See 3 publications below
• IHC: See 4 publications below
• IF: See 1 publications below

Produktinformation

15812-1-AP bindet in WB, IHC, IF, ELISA UBE2O und zeigt Reaktivität mit human

• Getestete Reaktivität: human
• In Publikationen genannte Reaktivität: human
• Wirt / Isotyp: Kaninchen / IgG
• Klonalität: Polyklonal
• Typ: Antikörper
• Immunogen: UBE2O fusion protein Ag8580
• Vollständiger Name: ubiquitin-conjugating enzyme E2O
• Berechnetes Molekulargewicht: 1292 aa, 141 kDa
• Beobachtetes Molekulargewicht: 150 kDa, 200-230 kDa
• GenBank-Zugangsnummer: BC007822
• Gene symbol: UBE2O
• Gene ID (NCBI): 63893
• Konjugation: Unkonjugiert
• Form: Liquid
• Reinigungsmethode: Antigen-Affinitätsreinigung
• Lagerungspuffer: PBS mit 0.02% Natriumazid und 50% Glycerin pH 7.3.
• Lagerungsbedingungen: Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

UBE2O, also named as KIAA1734, belongs to the ubiquitin-conjugating enzyme family. It catalyzes the covalent attachment of ubiquitin to other proteins. UBE2O has a calculated molecular mass of 141 kDa, and many bands can be detected as 140-170 kDa and 200-230 kDa (PMID: 28774900, 23455153, 28774922, 11311559).

Publikationen

Species	Application	Title
human	IHC	Front Cell Dev Biol; Long Noncoding RNA HCG18 Promotes Malignant Phenotypes of Breast Cancer Cells via the HCG18/miR-103a-3p/UBE2O/mTORC1/HIF-1α-Positive Feedback Loop.; Authors - Xu Liu
human	IHC,WB	Int J Med Sci; UBE2O promotes hepatocellular carcinoma cell proliferation and invasion by regulating the AMPKα2/mTOR pathway; Authors - Zhan Shi ; KD Validated
human	WB,IHC,IF	Cell Death Dis; UBE2O promotes the proliferation, EMT and stemness properties of breast cancer cells through the UBE2O/AMPKα2/mTORC1-MYC positive feedback loop.; Authors - Xu Liu ; KD Validated
human	IHC,WB	Curr Med Sci; High Level of Ubiquitin Conjugate Enzyme E2O Indicates Poor Prognosis of Patients with Hepatocellular Carcinoma; Authors - Si-Yu Lan